The Filing Desk

Aclaris Therapeutics vs Precigen

Aclaris Therapeutics ACRS · Precigen PGEN · Pharmaceuticals

Precigen reported revenue of $10 million in fiscal 2025, 1.2 times Aclaris Therapeutics' $8 million in fiscal 2025. Aclaris Therapeutics' revenue fell 58.2% in its latest year, and Precigen's grew 146.7%. Aclaris Therapeutics had an operating margin of -975.9%, against -1141.1% at Precigen. Free cash flow was −$47 million at Aclaris Therapeutics and −$90 million at Precigen.

Side by side

Aclaris TherapeuticsPrecigen
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$8M$10M
Revenue growth−58.2%146.7%
Revenue growth a year, last 5 years3.7%−21.2%
Gross margin73.3%—
Operating margin−975.9%−1,141.1%
Net margin−829.6%−2,588.2%
Free cash flow−$47M−$90M
Free cash flow margin−603.4%−927.6%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count58.6%16.9%
Last close$3.92$4.54
P/E at the last close—45.4×
Insider trades, last 12 months——
Piotroski F-score—2 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Aclaris TherapeuticsPrecigen
Operating margin
Percent of revenue
Aclaris TherapeuticsPrecigen
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Aclaris TherapeuticsPrecigen

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Aclaris Therapeutics and Precigen pages.